(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -2.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Biontech Se's revenue in 2025 is $3,386,352,941.On average, 6 Wall Street analysts forecast BNTX's revenue for 2025 to be $696,015,489,470, with the lowest BNTX revenue forecast at $486,109,940,577, and the highest BNTX revenue forecast at $1,013,488,082,573. On average, 7 Wall Street analysts forecast BNTX's revenue for 2026 to be $704,109,509,053, with the lowest BNTX revenue forecast at $409,549,698,323, and the highest BNTX revenue forecast at $986,477,567,565.
In 2027, BNTX is forecast to generate $751,898,360,343 in revenue, with the lowest revenue forecast at $421,172,681,596 and the highest revenue forecast at $990,838,289,729.